Greater than 80% of patients with HNSCC have a combined positive score of >1 indicative of PD-L1 positivity (Chow et al., 2016), but significant heterogeneity of PD-L1 expression exists within individual tumors (Rasmussen et al., 2019). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.